Thao K Le

US Patent:

8497240, Jul 30, 2013

Filed:

Aug 17, 2007

Appl. No.:

12/377856

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Samuel Janssen - San Marcos CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - Palo Alto CA, US
Christopher J. Soares - La Jolla CA, US
Ved Srivastava - Cary NC, US
Andrew A. Young - Chapel Hill NC, US
Thao Le - Carlsbad CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
A61K 38/16
A61K 38/26

US Classification:

514 69, 514 213, 514 72, 514 117, 530324, 530308

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

20080312157, Dec 18, 2008

Filed:

Aug 17, 2007

Appl. No.:

11/840921

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Thao Le - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00
C07K 7/00
A61P 1/00

US Classification:

514 15, 530328

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

20130137631, May 30, 2013

Filed:

Aug 22, 2012

Appl. No.:

13/591677

Inventors:

Odile Esther LEVY - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra G. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Thao Le - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA

International Classification:

C07K 14/575
C07K 7/06

US Classification:

514 53, 530300, 514 69, 514 97, 514 68, 530324

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

20130281374, Oct 24, 2013

Filed:

Apr 23, 2013

Appl. No.:

13/868891

Inventors:

Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Samuel Janssen - San Marcos CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - Palo Alto CA, US
Christopher J. Soares - La Jolla CA, US
Ved Srivastava - Cary NC, US
Andrew A. Young - Chapel Hill NC, US
Thao Le - Carlsbad CA, US

International Classification:

C07K 14/47

US Classification:

514 117, 514 164, 514 97

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.